<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072497</url>
  </required_header>
  <id_info>
    <org_study_id>2017L04524-Ⅰ/Ⅱ</org_study_id>
    <nct_id>NCT04072497</nct_id>
  </id_info>
  <brief_title>A Clinical Study of a Zoster Vaccine in Healthy Adults &gt;= 40 Years</brief_title>
  <official_title>A Safety and Immunogenicity Study of a Zoster Vaccine in Healthy Adults &gt;= 40 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute Of Biological Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Institute Of Biological Products</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical&#xD;
      syndromes.Primary infection is manifested as varicella (chickenpox), whereas reactivation of&#xD;
      latent VZV results in a localized eruption known as herpes zoster. Most people 40 years of&#xD;
      age or older had evidence of previous VZV infection. This study plans to have 522 adults&#xD;
      above 40 years old involoved in a randomized, double-blind, placebo-controlled trial of an&#xD;
      investigational live attenuated zoster vaccine. The investigational vaccine is produced by&#xD;
      Shanghai Institute of Biological Products Co., Ltd. The safety and immunogenicity of the&#xD;
      zoster vaccine is evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactogenicity in the group of live attenuated zoster vaccine</measure>
    <time_frame>0 days-6 months after the vaccination</time_frame>
    <description>The incidence rate of subjects with solicited AE(s) with 95% confidence interval&#xD;
The incidence rate of subjects with solicited SAE(s) with 95% confidence interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VZV specific serum conversion rate</measure>
    <time_frame>30 days after the vaccination</time_frame>
    <description>VZV specific serum conversion is defined as: if serum antibody titer before immunization was less than 1: 8, and antibody titer after immunization was ≥ 1: 8. Or the antibody titer before immunization was≥1:8, and the antibody titer after immunization≥4-fold increase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VZV specific serum geometric mean titre</measure>
    <time_frame>30 days after the vaccination</time_frame>
    <description>For each group serum titre with FAMA test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VZV specific serum geometric mean fold increase</measure>
    <time_frame>30 days after the vaccination</time_frame>
    <description>For each group serum titre with FAMA test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reactogenicity in the group of live attenuated varicella vaccine</measure>
    <time_frame>0 days-6 months after the vaccination</time_frame>
    <description>The incidence rate of subjects with solicited AE(s) with 95% confidence interval&#xD;
The incidence rate of subjects with solicited SAE(s) with 95% confidence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactogenicity in the group of placebo</measure>
    <time_frame>0 days-6 months after the vaccination</time_frame>
    <description>The incidence rate of subjects with solicited AE(s) with 95% confidence interval&#xD;
The incidence rate of subjects with solicited SAE(s) with 95% confidence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The immunogenicity persistence of antibody titer</measure>
    <time_frame>90 days-360 days after vaccination</time_frame>
    <description>The antibody titer measured by FAMA postvaccination in day 90,180,360</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">522</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Zoster vaccine, Live</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>live attenuated varicella-zoster virus vaccine (with live virus &gt;=4.3 LgPFU per dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varicella vaccine, Live</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>live attenuated varicella-zoster virus vaccine (with live virus &gt;=3.3 LgPFU per dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with no live virus</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>One shot of the zoster vaccine</intervention_name>
    <description>One shot of the zoster vaccine (with live virus &gt;=4.3 LgPFU per dose)</description>
    <arm_group_label>Zoster vaccine, Live</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>One shot of the varicella vaccine</intervention_name>
    <description>One shot of the varicella vaccine (with live virus &gt;=3.3 LgPFU per dose)</description>
    <arm_group_label>Varicella vaccine, Live</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>one shot of placebo</intervention_name>
    <description>one shot of placebo with no live virus</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers aged over 40 years (male or female).&#xD;
&#xD;
          -  Able to comply with all clinical trial protocol requirements and willing to complete&#xD;
             all the visit plan process during the whole clinical trial observation period.&#xD;
&#xD;
          -  Able to understand the content of informed consent and willing to sign the informed&#xD;
             consent.&#xD;
&#xD;
          -  Able to complete the diary card independently.&#xD;
&#xD;
          -  Patients with chronic diseases need to be in a stable period.&#xD;
&#xD;
          -  Axillary temperature ≤37.0°C.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of herpes zoster.&#xD;
&#xD;
          -  Prior history of vaccination with herpes zoster vaccine or chickenpox vaccine.&#xD;
&#xD;
          -  History of allergic disease likely to be exacerbated by any component of the vaccine.&#xD;
&#xD;
          -  Taking immunoglobulins and/or any blood products within the last 3 months or will&#xD;
             receive these products during the study period.&#xD;
&#xD;
          -  Taking certain pharmaceuticals to be like salicylate kind, including aspirin, and&#xD;
             difluorosalicylic, or going to take these medicine during the study period.&#xD;
&#xD;
          -  Participation in another research study involving receipt of an investigational&#xD;
             product in the last 30 days.&#xD;
&#xD;
          -  Prior administration of live vaccine in last 30 days.&#xD;
&#xD;
          -  Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in&#xD;
             last 14 days.&#xD;
&#xD;
          -  History of serious disease and the participation in the clinical trial is likely to&#xD;
             increase the disease risk and interfere with the observation of clinical trial index.&#xD;
&#xD;
          -  Taking immunosuppressive therapy in last 6 months.&#xD;
&#xD;
          -  Any autoimmune disease or immunodeficient state, autoimmune disease or immunodeficient&#xD;
             disease.&#xD;
&#xD;
          -  Active tuberculosis patient.&#xD;
&#xD;
          -  Acute or chronic infections at the vaccination day (axillary temperature≥ 38.0°C).&#xD;
&#xD;
          -  Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet&#xD;
             disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed.&#xD;
&#xD;
          -  Woman who is breast-feeding.&#xD;
&#xD;
          -  Previous history of mental and neurological diseases (e.g. depression, epilepsy or&#xD;
             convulsion)&#xD;
&#xD;
          -  Planned to move before the end of the study or leave the country for a long time&#xD;
             during the scheduled study visit.&#xD;
&#xD;
          -  Abnormal Blood Routine and Biochemical Indexes before Inoculation (except for minor&#xD;
             abnormalities that are not clinically significant as judged by doctors)&#xD;
&#xD;
          -  Any other conditions may compromise the safety or availability of participants in the&#xD;
             judgment of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Henan Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Qixian</city>
        <state>Henan</state>
        <zip>450016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VZV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT04072497/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

